0001867096-24-000016.txt : 20240131 0001867096-24-000016.hdr.sgml : 20240131 20240131170455 ACCESSION NUMBER: 0001867096-24-000016 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240131 FILED AS OF DATE: 20240131 DATE AS OF CHANGE: 20240131 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: JOHNSON KENNETH ERLAND CENTRAL INDEX KEY: 0001743774 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40880 FILM NUMBER: 24583841 MAIL ADDRESS: STREET 1: C/O XERIS PHARMACEUTICALS, INC. STREET 2: 180 N. LASALLE STREET, SUITE 1800 CITY: CHICAGO STATE: IL ZIP: 60601 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Xeris Biopharma Holdings, Inc. CENTRAL INDEX KEY: 0001867096 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 871082097 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1375 WEST FULTON STREET, SUITE 1300 CITY: CHICAGO STATE: IL ZIP: 60607 BUSINESS PHONE: 844-445-5704 MAIL ADDRESS: STREET 1: 1375 WEST FULTON STREET, SUITE 1300 CITY: CHICAGO STATE: IL ZIP: 60607 4 1 wk-form4_1706738685.xml FORM 4 X0508 4 2024-01-31 0 0001867096 Xeris Biopharma Holdings, Inc. XERS 0001743774 JOHNSON KENNETH ERLAND C/O XERIS BIOPHARMA HOLDINGS, INC. 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607 0 1 0 0 See Remarks 0 Common Stock 2024-01-31 4 A 0 175000 0 A 446860 D These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years. These shares include 2,077 shares that were purchased on June 30, 2023 due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan. Senior Vice President, Global Development and Medical Affairs /s/ Beth Hecht, as Attorney-in-Fact 2024-01-31